There are 2789 resources available
766P - Mapping BRCA1/2 variants in ovarian cancer patients: Contribution of a BRCA2 founder effect
Presenter: Teresa Duarte
Session: ePoster Display
767P - Retrospective analysis of the impact of bevacizumab dose-intensity on the survival of platinum-resistant ovarian cancer patients
Presenter: Jose Bahena
Session: ePoster Display
768P - P-cadherin prognostic significance in high-grade serous ovarian cancer wildtype for BRCA1/2
Presenter: Rita Canario
Session: ePoster Display
769P - Urinary microRNAs as biomarkers for early detection of ovarian cancer
Presenter: Shinichi Tate
Session: ePoster Display
770P - Wild-type BRCA1/2 ovarian cancer: Prospective follow-up data from a multidisciplinary program
Presenter: Inês Oliveira
Session: ePoster Display
771P - Mutational landscape and clonal evolution of coexisting ovarian cancer and borderline tumor
Presenter: Lei Li
Session: ePoster Display
772P - Hormonal therapy in pretreated patients with metastatic or refractory ovary granulosa cell tumor
Presenter: Izzet Dogan
Session: ePoster Display
773P - Prognostic value of preoperative soluble interleukin 2 receptor α as a novel immune biomarker in epithelial ovarian cancer
Presenter: Hui Li
Session: ePoster Display
774P - Anlotinib plus sintilimab in patients with recurrent advanced cervical cancer: A prospective, multicenter, single-arm, phase II clinical trial
Presenter: Qin Xu
Session: ePoster Display
775P - Tremelimumab (T) + durvalumab (D) combined with metronomic oral vinorelbine (MOV): Results of the recurrent cervical cancer (RCC) cohort of the MOVIE study
Presenter: Jean-Sebastien Frenel
Session: ePoster Display